U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Jadad AR, Boyle M, Cunningham C, et al. Treatment of Attention-Deficit/Hyperactivity Disorder. Rockville (MD): Agency for Healthcare Research and Quality (US); 1999 Nov. (Evidence Reports/Technology Assessments, No. 11.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Treatment of Attention-Deficit/Hyperactivity Disorder

Treatment of Attention-Deficit/Hyperactivity Disorder.

Show details

References

  1. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ Placebo-controlled evaluation of Ritalin side effects. Pediatrics. 1993 Jun;91(6):1101–6. [PMC free article: PMC375534] [PubMed: 8502509]
  2. American Academy of Child and Adolescent Psychiatry Practice parameters for the assessment and treatment of children, adolescents and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997a;36(Suppl 10):85S–121S. [PubMed: 9334567]
  3. American Academy of Child and Adolescent Psychiatry Summary of practice parameters for the assessment and treatment of children, adolescents and adults with ADHD. J Am Acad Child Adolesc Psychiatry. 1997b;36:1311–7. [PubMed: 9291734]
  4. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association; 1994.
  5. Arnold LE, Christopher J, Huestis R, Smeltzer DJ Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: Controlled comparison by placebo washout design with Bayes' analysis. Arch Gen Psychiatry. 1978 Apr;35(4):463–73. [PubMed: 365123]
  6. Arnold LE, Huestis RD, Smeltzer DJ, Scheib J, Wemmer D, Colner G Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arch Gen Psychiatry. 1976 Mar;33(3):292–301. [PubMed: 769721]
  7. Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, Tobin K Gamma-linolenic acid for attention-deficit hyperactivity disorder: Placebo-controlled comparison to d-amphetamine. Biol Psychiatry. 1989;25:222–8. [PubMed: 2539203]
  8. Barkley, RA Attention-deficit/hyperactivity disorder. In: Mash EJ and Barkley RA, editors. Child psychopathology. New York: Guildford; 1996. p. 63-112.
  9. Barkley RA, McMurray MB, Edelbrock CS, Robbins K The response of aggressive and nonaggressive ADHD children to two doses of methylphenidate. J Am Acad Child Adolesc Psychiatry. 1989;28 (6):873–81. [PubMed: 2808257]
  10. Barkley RA, McMurray MB, Edelbrock CS, Robbins K Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics. 1990 Aug;86(2):184–92. [PubMed: 2196520]
  11. Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, Schumacher E Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 May;34(5):649–57. [PubMed: 7775360]
  12. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):637–9. [PubMed: 8773637]
  13. Berlin JA Does blinding of readers affect the results of meta-analyses? University of Pennsylvania meta-analysis blinding study group. Lancet. 1997;350(9072):185–6. [PubMed: 9250191]
  14. Berman BM, Ezzo J, Hadhazy VA, Jadad AR, Lao L, Singh B Penetrating the methodological issues in randomized controlled trials of acupuncture and chronic pain: A systematic review. Forthcoming.
  15. Bero LA, Rennie D Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996;12:209–37. [PubMed: 8707496]
  16. Biederman J, Faraone SV, Keenan K Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1992;49:728–38. [PubMed: 1514878]
  17. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry. 1989a Nov;28(6):903–11. [PubMed: 2808261]
  18. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989b Sep;28(5):777–84. [PubMed: 2676967]
  19. Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry. 1993 Jan;32(1):199–204. [PubMed: 8428872]
  20. Biederman J, Milberger S, Faraone S, Kiely K, Guite J, Mick E, Ablon S, Warburton R, Reed E Family-environment risk factors for attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:464–70. [PubMed: 7771916]
  21. Borcherding BG, Keysor CS, Cooper TB, Rapoport JL Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology. 1989 Dec;2(4):255–63. [PubMed: 2692588]
  22. Borden, KA, Brown, RT Attributional outcomes: The subtle messages of treatments for attention deficit disorder. Cognitive Ther Res. 1989 Apr;13(2):147–60.
  23. Brown RT, Wynne ME, Medenis R Methylphenidate and cognitive therapy: A comparison of treatment approaches with hyperactive boys. J Abnorm Child Psychol. 1985 Mar;13(1):69–87. [PubMed: 3973253]
  24. Brown RT, Borden KA, Wynne ME, Schleser R, Clingerman SR Methylphenidate and cognitive therapy with ADD children: A methodological reconsideration. J Abnorm Child Psychol. 1986 Dec;14(4):481–97. [PubMed: 3782621]
  25. Brown RT, Borden KA, Wynne ME, Spunt AL Patterns of compliance in a treatment program for children with attention deficit disorder. J Compliance Health Care. 1988;3(1):23–39.
  26. Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, Kuiper M Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. J Child Psychol Psychiatry. 1996 Jul;37(5):587–95. [PubMed: 8807439]
  27. Cadoret RJ, Stewart MA An adoption study of attention deficit/hyperactivity/aggression and their relationship to adult antisocial personality. Compr Psychiatry. 1991;32:73–82. [PubMed: 2001624]
  28. Carlson CL, Pelham WEJ, Milich R, Dixon J Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol. 1992;20(2):213–32. [PubMed: 1593027]
  29. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):589–96. [PubMed: 9136492]
  30. Cho MK, Bero LA The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996;124:485–9. [PubMed: 8602706]
  31. Christensen DE Effects of combining methylphenidate and a classroom token system in modifying hyperactive behavior. Am J Ment Defic. 1975 Nov;80(3):266–76. [PubMed: 1103623]
  32. Conners CK, Taylor E Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Arch Gen Psychiatry. 1980 Aug;37(8):922–30. [PubMed: 7406656]
  33. Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67–73. [PubMed: 8927677]
  34. Conners CK, Taylor E, Meo G, Kurtz MA, Fournier M Magnesium pemoline and dextroamphetamine: A controlled study in children with minimal brain dysfunction. Psychopharmacologia. 1972;26(4):321–36. [PubMed: 4508756]
  35. Conrad WG, Dworkin ES, Shai A, Tobiessen JE Effects of amphetamine therapy and prescriptive tutoring on the behavior and achievement of lower class hyperactive children. J Learn Disabil. 1971;4:509–17.
  36. DeVeaugh-Geiss J, Joseph A Paradoxical response to amphetamine in a hyperkinetic adult. Psychosomatics. 1980;21(3):247–52. [PubMed: 7367570]
  37. Donnelly M, Zametkin AJ, Rapoport JL, Ismond DR, Weingartner H, Lane E, Oliver J, Linnoila M, Potter WZ Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther. 1986 Jan;39(1):72–81. [PubMed: 3510796]
  38. Efron D, Jarman F, Barker M Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Paediatrics. 1997;100(6):–. [PubMed: 9382907]
  39. Elia J, Ambrosini, PJ, Rapoport JL Treatment of attention-deficit/hyperactivity disorder. N Engl J Med. 1999 Mar;340(10):780–8. [PubMed: 10072414]
  40. Elia J, Borcherding BG, Rapoport JL, Keysor CS Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatry Res. 1991 Feb;36(2):141–55. [PubMed: 2017529]
  41. Ernst M, Liebenauer LL, Jons PH, Tebeka D, Cohen RM, Zametkin AJ Selegiline in adults with attention deficit hyperactivity disorder: Clinical efficacy and safety. Psychopharmacol Bull. 1996;32(3):327–34. [PubMed: 8961775]
  42. Ernst M, Liebenauer LL, Tebeka D, Jons PH, Eisenhofer G, Murphy DL, Zametkin AJ Selegiline in ADHD adults: Plasma monoamines and monoamine metabolites. (Same study as Ernst, Liebenauer, Jons et al., 1996). Neuropsychopharmacology. 1997 Apr;16(4):276–84. [PubMed: 9094145]
  43. Evans SW, Vallano G, Pelham W Treatment of parenting behavior with a psychostimulant: A case study of an adult with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1994;4(1):63–9.
  44. Fehlings DL, Roberts W, Humphries T, Dawe G Attention deficit hyperactivity disorder: Does cognitive behavioral therapy improve home behavior? J Dev Behav Pediatrics. 1991 Aug;12(4):223–8. [PubMed: 1939676]
  45. Fine S, Johnston C Drug and placebo side effects in methylphenidate-placebo trial for attention deficit hyperactivity disorder. Child Psychiatry Hum Dev. 1993;4(1):25–30. [PubMed: 8404241]
  46. Firestone P, Crowe D, Goodman JT, McGrath P Vicissitudes of follow-up studies: Differential effects of parent training and stimulant medication with hyperactives. Am J Orthopsychiatry. 1986 Apr;56(2):184–94. [PubMed: 3706498]
  47. Fitzpatrick PA, Klorman R, Brumaghim JT, Borgstedt AD Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1992;31:226–3. [PubMed: 1564023]
  48. Freiman JA, Chalmers TC, Smith H, Kuebler R The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978 Sep;299(13):690–4. [PubMed: 355881]
  49. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder [published erratum appears in Arch Gen Psychiatry 1995 Oct;52(10):836] Arch Gen Psychiatry. 1995 Jun;52(6):444–55. [PubMed: 7771914]
  50. Garfinkel BD, Webster CD, Sloman L Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder. Can J Psychiatry. 1981 Oct;26(6):395–401. [PubMed: 7028238]
  51. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, Eidevall-Wallin L, Gustafsson P, Kopp S Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997 Sep;54(9):857–64. [PubMed: 9294377]
  52. Gittelman-Klein R, Klein DF, Abikoff H, Katz S, Gloisten AC, Kates W Relative efficacy of methylphenidate and behavior modification in hyperkinetic children: An interim report. J Abnorm Child Psychol. 1976;4(4):361–79. [PubMed: 1002948]
  53. Gittelman-Klein R, Klein DF, Katz S, Saraf K, Pollack E Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results. Arch Gen Psychiatry. 1976 Oct;33(10):1217–31. [PubMed: 971031]
  54. Gittelman-Klein R, Landa B, Mattes JA, Klein DF Methylphenidate and growth in hyperactive children. Arch Gen Psychiatry. 1988;45:1127–30. [PubMed: 3058088]
  55. Goldman LS, Genel M, Bezman RJ, Slanetz PJ Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA. 1998;279(14):1100–7. [PubMed: 9546570]
  56. Greenberg LM, Deem MA, McMahon S Effects of dextroamphetamine, chlorpromazine, and hydroxyzine on behavior and performance in hyperactive children. Am J Psychiatry. 1972 Nov;129(5):532–9. [PubMed: 4562464]
  57. Greenhill LL, Rieder RO, Wender PH, Buchsbaum M, Zhan TP Lithium carbonate in the treatment of hyperactive children. Arch Gen Psychiatry. 1973 May;28(5):636–40. [PubMed: 4573417]
  58. Gross MD A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction. Dis Nerv Syst. 1976 Jan;37(1):14–6. [PubMed: 1106966]
  59. Gualtieri CT, Evans RW Motor performance in hyperactive children treated with imipramine. Percept Mot Skills. 1988 Jun;66(3):763–9. [PubMed: 3043370]
  60. Gualtieri CT, Keenan PA, Chandler M Clinical and neuropsychological effects of desipramine in children with attention deficit hyperactivity disorder. J Clin Psychopharmacol. 1991 Jun;11(3):155–9. [PubMed: 2066453]
  61. Handen BL, Feldman H, Gosling A, Breaux AM, McAuliffe S Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry. 1991 Mar;30(2):241–5. [PubMed: 2016228]
  62. Hinshaw SP, Buhrmester D, Heller T Anger control in response to verbal provocation: Effects of stimulant medication for boys with ADHD. J Abnorm Child Psychol. 1989 Aug;17(4):393–407. [PubMed: 2677081]
  63. Hinshaw SP, Henker B, Whalen CK Cognitive-behavioral and pharmacologic interventions for hyperactive boys: Comparative and combined effects. J Consult Clin Psychol. 1984 Oct;52(5):739–49. [PubMed: 6501659]
  64. http://www. healthy.net/library/books/ullman/chap3.htm
  65. Ioannidis JPA, Cappelleri JC, Lau J Issues in comparisons between meta-analyses and large trials. JAMA. 1998;279:1089–93. [PubMed: 9546568]
  66. Jadad AR, Rennie D The randomized controlled trial gets a middle-aged checkup. (Editorial). JAMA. 1998;279(4):319–20. [PubMed: 9450719]
  67. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials. 1996;17:1–12. [PubMed: 8721797]
  68. Jensen P, Martin D, Cantwell D Comorbidity in ADHD: Implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry. 1997;36(8):1065–79. [PubMed: 9256586]
  69. Kahn KS, Daya S, Jadad AR The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996 Mar 25;156:661–6. [PubMed: 8629879]
  70. Kauffman RE, Smith-Wright D, Reese CA, Simpson R, Jones F Medication compliance in hyperactive children. Pediatr Pharmacol. 1981;1(3):231–7. [PubMed: 7346742]
  71. Kavale K The efficacy of stimulant drug treatment for hyperactivity: A meta-analysis. J Learn Disabil. 1982 May;15(5):280–9. [PubMed: 6123539]
  72. Kewley GD Personal paper: Attention deficit hyperactivity disorder is underdiagnosed and undertreated in Britain. BMJ. 1998;316:1594–6. [PMC free article: PMC1113204] [PubMed: 9596603]
  73. Klein RG, Abikoff H Behavior therapy and methylphenidate in the treatment of children with ADHD. (Same study as Gittelman-Klein, Klein, Abikoff et al., 1976). J Attention Dis. 1997;2(2):89–114.
  74. Klorman R, Coons HW, Borgstedt AD Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder: I. Clinical findings [published erratum appears in J Am Acad Child Adolesc Psychiatry 1987 Sep; 26(5): 820] J Am Acad Child Adolesc Psychiatry. 1987;26(3):363–7. [PubMed: 3298201]
  75. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1990 Sep;29(5):702–9. [PubMed: 2228922]
  76. Kupietz SS, Winsberg BG, Richardson E, Maitinsky S Effects of methylphenidate dosage in hyperactive reading-disabled children: I. Behavior and cognitive performance effects. J Am Acad Child Adolesc Psychiatry. 1988 Jan;27(1):70–7. [PubMed: 3343209]
  77. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V Users' guide to the medical literature IV: How to use an article about harm. JAMA. 1994;271(20):1615–9. [PubMed: 8182815]
  78. Levy F, Hobbes G Does haloperidol block methylphenidate? Motivation or attention? Psychopharmacology. 1996 Jul;126(1):70–4. [PubMed: 8853219]
  79. Linden M, Habib T, Radojevic V A controlled study of the effects of EEG biofeedback on cognition and behavior of children with attention deficit disorder and learning disabilities. Biofeedback Self Regul. 1996 Mar;21(1):35–49. [PubMed: 8833315]
  80. Long N, Rickert VI, Ashcraft EW Bibliotherapy as an adjunct to stimulant medication in the treatment of attention-deficit hyperactivity disorder. J Pediatr Health Care. 1993 Mar;7(2):82–8. [PubMed: 8492283]
  81. Matochik JA, Liebenauer LL, King C, Szymanski HV, Cohen RM, Zametkin AJ Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. Am J Psychiatry. 1994;151(5):658–64. [PubMed: 8166305]
  82. Mattes JA, Boswell L, Oliver H Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry. 1984 Nov;41(11):1059–63. [PubMed: 6388523]
  83. Miller A, Lee SK, Raina P, Klassen A, Zupancic J, Olsen L A review of therapies for attention-deficit/hyperactivity disorder. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998. RFP #ADHD-1196 http://www.ccohta.ca/main-e.html.
  84. Moher D, Dulberg CS, Wells GA Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994 Jul;272(2):122–4. [PubMed: 8015121]
  85. Moher D, Pham B, Jones A, Cook D, Jadad A, Moher M, Tugwell P, Klassen T Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–13. [PubMed: 9746022]
  86. MTA Cooperative Group 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. 1999. Submitted for publication. [PubMed: 10591283]
  87. NIH Consensus Statement Online Diagnosis and treatment of attention deficit hyperactivity disorder. 1998 Nov 16-18;16(2): http://odp.od.nih.gov/consensus. [PubMed: 10868163]
  88. Orford E Commentary: Diagnosis needs tightening. BMJ. 1998;316:1594–6. [PMC free article: PMC1113204]
  89. Ottenbacher KJ, Cooper HM Drug treatment of hyperactivity in children. Dev Med Child Neurol. 1983 Jun;25(3):358–66. [PubMed: 6347775]
  90. Oxman AD, Guyatt GH Validation of an index of the quality of review articles. J Clin Epidemiol. 1991;44:1271–8. [PubMed: 1834807]
  91. Pelham WEJ, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J Consult Clin Psychol. 1993;61(3):506–15. [PubMed: 8326053]
  92. Pelham WEJ, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics. 1990 Aug;86(2):226–37. [PubMed: 2196522]
  93. Pelham WEJ, Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Milich R, Moorer S Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics. 1987 Oct;80(4):491–501. [PMC free article: PMC138812] [PubMed: 3658567]
  94. Pliszka SR Comorbidity of attention-deficit hyperactivity disorder and overanxious disorder. J Am Acad Child Adolesc Psychiatry. 1992;31:197–203. [PubMed: 1564019]
  95. Quinn PO, Rapoport JL One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry. 1975 Mar;132(3):241–5. [PubMed: 1090193]
  96. Rapport MD, Carlson GA, Kelly KL, Pataki C Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry. 1993 Mar;32(2):333–42. [PubMed: 8444762]
  97. Reimherr FW, Wender PH, Ebert MH, Wood DR Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Res. 1984 Jan;11(1):71–8. [PubMed: 6200893]
  98. Richardson E, Kupietz SS, Winsberg BG, Maitinsky S, Mendell N Effects of methylphenidate dosage in hyperactive reading-disabled children: II. Reading achievement. J Am Acad Child Adolesc Psychiatry. 1988;27(1):78–87. [PubMed: 3343210]
  99. Richters JE, Arnold IE, Jensen PS, Abikoff H, Conners CK, Greenhill LL, Hechtman L, Hinshaw SP, Pelham WE, Swanson JM NIMH Collaborative Multisite Multimodal Treatment Study of children with ADHD: I. Background and rationale. J Am Acad Child Adolesc Psychiatry. 1995 Aug;34(8):987–1000. [PubMed: 7665456]
  100. Sackett DL, Richardson WS, Rosenberg W, Haynes RB Evidence-based medicine: How to practice and teach EBM. New York: Churchill Livingstone; 1997.
  101. Schachar RJ, Tannock R, Cunningham C, Corkum PV Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):754–63. [PubMed: 9183129]
  102. Schechter MD, Timmons GD Objectively measured hyperactivity -- II. Caffeine and amphetamine effects. J Clin Pharmacology. 1985 May;25(4):276–80. [PubMed: 4008672]
  103. Schulz KF, Chalmers I, Hayes RJ, Altman DG Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–12. [PubMed: 7823387]
  104. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: A double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995 Jan;95(1):74–81. [PMC free article: PMC161813] [PubMed: 7770313]
  105. Solanto MV, Wender EH, Bartell SS Effects of methylphenidate and behavioral contingencies on sustained attention in attention-deficit hyperactivity disorder: A test of the reward dysfunction hypothesis. J Child Adolesc Psychopharmacol. 1997;7(2):123–36. [PubMed: 9334897]
  106. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995 Jun;52(6):434–43. [PubMed: 7771913]
  107. Spring C, Yellin AM, Greenberg L Effects of imipramine and methylphenidate on perceptual-motor performance of hyperactive children. Percept Mot Skills. 1976 Oct;42(43):459–70. [PubMed: 790293]
  108. Srinivas NR, Hubbard JW, Quinn D, Midha KK Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther. 1992 Nov;52(5):561–8. [PubMed: 1424430]
  109. Stein MA, Blondis TA, Schnitzler ER, O'Brien T, Fishkin J, Blackwell B, Szumowski E, Roizen NJ Methylphenidate dosing: Twice daily versus three times daily. Pediatrics. 1996 Oct;98(4 Pt 1):748–56. [PubMed: 8885956]
  110. Stephens RS, Pelham WE, Skinner R State-dependent and main effects of methylphenidate and pemoline on paired-associate learning and spelling in hyperactive children. J Consult Clin Psychol. 1984;52(1):104–13. [PubMed: 6699239]
  111. Szatmari P, Offord DR, Boyle MH Ontario Child Health Study: Prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry. 1989;30:219–30. [PubMed: 2708462]
  112. Thurber S, Walker CE Medication and hyperactivity: A meta-analysis. J Gen Psychology. 1983 Jan;108(1st half):79–86. [PubMed: 6131929]
  113. Weinberg WA, Brumback RA The myth of attention-deficit-hyperactivity disorder: Symptoms resulting from multiple causes. J Child Neurology. 1992;7:431–45. [PubMed: 1469255]
  114. Wender PH, Reimherr FW, Wood DR Attention deficit disorder ("minimal brain dysfunction") in adults. A replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981 Apr;38(4):449–56. [PubMed: 7011250]
  115. Wender PH, Reimherr FW, Wood D, Ward M A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 1985 May;142(5):547–52. [PubMed: 3885760]
  116. Werry JS, Aman MG, Diamond E Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry. 1980 Jan;21(1):27–35. [PubMed: 7358801]
  117. Whitehouse D, Shah U, Palmer FB Comparison of sustained-release and standard methylphenidate in the treatment of minimal brain dysfunction. J Clin Psychiatry. 1980 Aug;41(8):282–5. [PubMed: 7400107]
  118. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147–53. [PubMed: 8780417]
  119. Winsberg BG, Kupietz SS, Yepes LE, Goldstein S Ineffectiveness of imipramine in children who fail to respond to methylphenidate. J Autism Dev Disord. 1980 Jun;10(2):129–37. [PubMed: 6765502]
  120. Winsberg BG, Press M, Bialer I, Kupietz S Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children. Pediatrics. 1974 Feb;53(2):236–41. [PMC free article: PMC126268] [PubMed: 4590730]
  121. Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319–24. [PubMed: 8714320]
  122. Wood DR, Reimherr FW, Wender PH Treatment of attention deficit disorder with dl-phenylalanine. Psychiatry Res. 1985 Sep;16(1):21–6. [PubMed: 3903813]

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...